Satsuma Pharmaceuticals, Inc.   Report issue

For profit Phase 3
Founded: San Francisco CA United States (2016)
Status: Acquired by Shin Nippon Biomedical Laboratories (2023)

Organization Overview

First Clinical Trial
2018
NCT03874832
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Satsuma Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

dihydroergotamine (D.H.E. 45) (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Migraine Disorders (Phase 3)

Migraine with Aura (Phase 3)

Migraine without Aura (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 1